Company Update

AI SummaryClose X

Trellus Health plc announced that cost-saving measures have extended their cash runway to early December 2025, beyond the previously announced early November timeline. The company anticipates reducing its average monthly cash burn from approximately $440,000 to around $395,000. Contract negotiations are in late stages for one collaboration with a leading global CRO to support a mid-stage clinical trial. Negotiations are progressing on a separate collaboration with a second leading global CRO following the company being granted preferred vendor status. Discussions with prospective investors regarding potential equity fundraising are ongoing, but there is no certainty that any funding transaction will be concluded.

Disclaimer*

UK 100

Latest directors dealings